Xiao Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xiao Wang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Hong-Li Li
Children’s Hospital Affiliated of Zhengzhou University, Henan Children’s Hospital, Zhengzhou Children’s Hospital, Zhengzhou 450018, China
1 shared publication - Jian Song
Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China
1 shared publication - Lu-Lu Dong
School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China
1 shared publication - Mei-Qi Jia
School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China
1 shared publication - Min-Jie Jin
School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China
1 shared publication - Qian-Yu Li
School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China
1 shared publication
Latest Publications
- Open Access
A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle
Neuroblastoma has obvious heterogeneity. It is one of the few undifferentiated malignant tumors that can spontaneously degenerate into completely benign tumors. However, for its high-risk type, even with various intensive treatment options, the prognosis is still unsatisfactory. At the same time, a large number of research data show that the abnormal amplification and high-level expression of the MYCN gene are positively correlated with the malignant progression, poor prognosis, and mortality of neuroblastoma. In this context, this article explores the role of the N-Myc, MYCN gene expression product on its target genes related to the cell cycle and reveals its regulatory network in promoting tumor proliferation and malignant progression. We hope it can provide ideas and direction for the research and development of drugs targeting N-Myc and its downstream target genes.
Open AccessA Review of the Regulatory Mechanisms of N-Myc on Cell Cycle
Neuroblastoma has obvious heterogeneity. It is one of the few undifferentiated malignant tumors that can spontaneously degenerate into completely benign tumors. However, for its high-risk type, even with various intensive treatment options, the prognosis is still unsatisfactory. At the same time, a large number of research data show that the abnormal amplification and high-level expression of the MYCN gene are positively correlated with the malignant progression, poor prognosis, and mortality of neuroblastoma. In this context, this article explores the role of the N-Myc, MYCN gene expression product on its target genes related to the cell cycle and reveals its regulatory network in promoting tumor proliferation and malignant progression. We hope it can provide ideas and direction for the research and development of drugs targeting N-Myc and its downstream target genes.